Heart Failure and MEF2 Transcriptome Dynamics in Response to β-Blockers

Abstract Myocyte Enhancer Factor 2 (MEF2) mediates cardiac remodelling in heart failure (HF) and is also a target of β-adrenergic signalling, a front-line treatment for HF. We identified global gene transcription networks involved in HF with and without β-blocker treatment. Experimental HF by transv...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: S. W. Tobin, S. Hashemi, K. Dadson, S. Turdi, K. Ebrahimian, J. Zhao, G. Sweeney, J. Grigull, J. C. McDermott
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
R
Q
Acceso en línea:https://doaj.org/article/d8d5bdb28cbb420387d3534659928246
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!